Navigation Links
OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies
Date:1/20/2011

ROCKVILLE, Md., Jan. 20, 2011 /PRNewswire/ -- OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity. Greater than 50% of all TrueMAB antibodies are validated for immunohistochemistry and for flow cytomtery applications.

Monoclonal antibodies have become invaluable tools for researchers developing diagnostic tests and novel therapeutics.  In 2010, OriGene announced its commitment to build the world's largest monoclonal antibody facility capable of producing over 20,000 TrueMAB antibodies per year. Recently, OriGene has released its 1,500th monoclonal antibody and hybridoma cell line under the TrueMAB brand name.

"We are extremely pleased with OriGene's progress in achieving this significant milestone in less than a year. Our antibody performance and hybridoma development capabilities have uniquely positioned us as an instrumental partner for diagnostic and research assay development. We fully anticipate releasing 400-500 new mouse monoclonal antibodies per month by end of 2011 as we head towards our ultimate goal," commented Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies.

TrueMAB antibodies and hybridoma cell lines from OriGene are generated using OriGene's large collection of full-length human proteins as primary antigens that have been affinity purified under native conditions to preserve natural protein conformations.  As a result, TrueMAB antibodies provide high sensitivity and specificity for the recognition of native epitopes on the protein's natural conformational structure.  With the introduction of TrueMAB antibodies, each included with an over-expression control protein lysate, OriGene now provides higher quality and greater numbers of monoclonal antibodies for diagnostic and research applications.

All TrueMAB antibodies are routinely validated for critical applications such as immunohistochemistry, immunofluorescent staining, flow cytometry, immunoprecipitation, and Western blot analysis. The hybridoma cell lines are available for immediate licensing to partnering organizations.

To learn more about OriGene's TrueMAB mouse monoclonal antibody development program and hybridoma cell line licensing opportunities, please visit www.origene.com/antibody/TrueMAB or contact businessdev@origene.com.

About OriGene Technologies

OriGene Technologies, Inc., is a gene centric life sciences company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery.  OriGene develops proteins, antibodies, and other molecular tools to allow researchers to analyze their data on a multiplex level. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB™), 100,000 highly validated human tissues, and protein microarray products and services.  OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. For more information, visit www.origene.com.


'/>"/>
SOURCE OriGene Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
2. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
3. OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells
4. OriGene Technologies Acquires Marligen Biosciences
5. OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
6. OriGene Technologies, Inc. to Build the Worlds Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
7. OriGene Technologies Launches Over 5,000 Heavy Isotope Labeled Full-Length Human Proteins as Quantitative Internal Standards for SRM/MRM Mass Spectrometry
8. Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
9. Aureus Pharma Releases New Unified Knowledge Database
10. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
11. Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):